News

Research – Genprex (GNPX) – Initiation of Coverage

Health
0 min read

Friday, April 26, 2019

Genprex (GNPX)

Poised to Emerge as a Leader in Cancer Gene Therapy.

Genprex Inc is a US-based clinical stage gene therapy company. It is engaged in developing a new approach to treating cancer, based upon its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy.

Cosme Ordoñez, M.D., Ph. D. , Life Sciences Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating. 

  • Coverage
    Initiation
    . We are initiating coverage of Genprex, Inc. with an
    Outperform Rating and a 
    $5.00 target price.
  • Unique Gene
    Therapy Technology
    . We believe that Genprex will emerge as a leader in the area
    of gene therapy for the treatment of cancer. The Company is developing a unique
    platform technology consisting on the use of lipid nano…





    Get full report on Channelchek desktop.



*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.